Beyond market averages, investors looking for exceptional returns turn to stock picking. Skillful choices in individual stocks have the power to substantially increase your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
In the latest session, ARS Pharmaceuticals Inc (NASDAQ: SPRY) closed at $10.44 down -7.81% from its previous closing price of $11.33. In other words, the price has decreased by -$7.81 from its previous closing price. On the day, 1.17 million shares were traded. SPRY stock price reached its highest trading level at $11.6194 during the session, while it also had its lowest trading level at $10.14.
Ratios:
For a deeper understanding of ARS Pharmaceuticals Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 60.84 and its Current Ratio is at 60.84. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Leerink Partners on March 05, 2024, Upgraded its rating to Outperform and sets its target price to $18 from $6 previously.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Jul 16 ’24 when Tanimoto Sarina sold 100,000 shares for $11.40 per share. The transaction valued at 1,140,295 led to the insider holds 1,547,447 shares of the business.
Lowenthal Richard E sold 100,000 shares of SPRY for $1,140,295 on Jul 16 ’24. The PRESIDENT AND CEO now owns 1,547,447 shares after completing the transaction at $11.40 per share. On Jul 09 ’24, another insider, Tanimoto Sarina, who serves as the CHIEF MEDICAL OFFICER of the company, sold 100,000 shares for $9.62 each. As a result, the insider received 961,725 and left with 1,496,494 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, SPRY now has a Market Capitalization of 1012071360 and an Enterprise Value of 788655936. For the stock, the TTM Price-to-Sale (P/S) ratio is 101212.05 while its Price-to-Book (P/B) ratio in mrq is 4.51. Its current Enterprise Value per Revenue stands at 78865.59 whereas that against EBITDA is -12.734.
Stock Price History:
Over the past 52 weeks, SPRY has reached a high of $11.90, while it has fallen to a 52-week low of $2.55. The 50-Day Moving Average of the stock is 14.74%, while the 200-Day Moving Average is calculated to be 47.56%.
Shares Statistics:
For the past three months, SPRY has traded an average of 571.99K shares per day and 810820 over the past ten days. A total of 96.41M shares are outstanding, with a floating share count of 47.42M. Insiders hold about 51.06% of the company’s shares, while institutions hold 35.03% stake in the company. Shares short for SPRY as of 1719532800 were 6881590 with a Short Ratio of 12.03, compared to 1717113600 on 6818939. Therefore, it implies a Short% of Shares Outstanding of 6881590 and a Short% of Float of 13.389999999999999.